Table 1.
Baseline characteristics of the participants.
| MET group (n = 54) | SPI group (n = 53) | COM (n = 51) | P | |
|---|---|---|---|---|
| Age (years) | 27.0 ± 3.7 | 27.6 ± 3.7 | 27.2 ± 3.6 | >0.05 |
| Number of menstruation per year (normal ≥8/year) | 5.7 ± 2.1 | 6.1 ± 1.9 | 5.8 ± 1.8 | >0.05 |
| SBP (mm Hg) | 112 ± 11 | 124 ± 13 | 117 ± 9 | >0.05 |
| DBP (mm Hg) | 72 ± 13 | 79 ± 10 | 76 ± 8 | >0.05 |
| Weight (kg) | 63.2 ± 12.4 | 65.5 ± 16.8 | 56.5 ± 9.0 | <0.05 |
| BMI (kg/m2) | 25.6 ± 4.5 | 25.9 ± 6.7 | 25.4 ± 3.7 | >0.05 |
| WHR | 0.87 ± 0.07 | 0.87 ± 0.09 | 0.86 ± 0.09 | >0.05 |
| LH/FSH | 1.67 ± 0.95 | 1.86 ± 0.90 | 2.06 ± 0.99 | >0.05 |
| TC (mmol/L) | 4.81 ± 1.01 | 4.91 ± 1.40 | 4.74 ± 0.98 | >0.05 |
| TT (nmol/L) | 2.25 ± 1.25 | 2.09 ± 0.80 | 2.50 ± 1.03 | >0.05 |
| FAI | 6.71 ± 8.87 | 6.99 ± 5.26 | 7.07 ± 4.21 | >0.05 |
| QUICKI | 0.33 ± 0.03 | 0.34 ± 0.03 | 0.34 ± 0.03 | >0.05 |
| HOMA-IR | 3.30 ± 2.34 | 3.02 ± 1.90 | 2.47 ± 1.63 | >0.05 |
| HOMA-β | 224.6 ± 166.8 | 299.6 ± 381 | 179.9 ± 99 | >0.05 |
| FPG (mmol/L) | 4.94 ± 0.63 | 4.79 ± 0.55 | 4.84 ± 0.61 | >0.05 |
| FINS (mU/L) | 14.95 ± 9.61 | 13.87 ± 8.08 | 11.24 ± 7.1 | >0.05 |
| mF-G score | 4.2 ± 2.1 | 4.2 ± 1.3 | 4.1 ± 1.4 | >0.05 |
| AUCins | 289.6 ± 151 | 282.5 ± 146.4 | 267.8 ± 126 | >0.05 |
| AUCglu | 22.8 ± 5.4 | 21.0 ± 4.8 | 20.5 ± 5.0 | >0.05 |
| Rosenfield score | 0.89 ± 1.01 | 0.90 ± 0.92 | 0.85 ± 1.05 | >0.05 |
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist-hip ratio; LH/FSH: luteinizing hormone/follicular-stimulating hormone; TC: total cholesterol; TT: total testosterone; FAI: free androgen index; QUICKI: quantitative insulin sensitivity check index; HOMA: homeostatic model assessment; IR: insulin resistance; FPG: fasting plasma glucose; FINS: fasting insulin; mG-G score: modified Ferriman–Gallwey score; AUCglu: oral glucose tolerance test area under curve-glucose; AUCins: oral glucose tolerance test area under curve-insulin.